Low-dose Btk inhibitors: an 'aspirin' of tomorrow?
Haematologica
.
2021 Jan 1;106(1):2-4.
doi: 10.3324/haematol.2020.265173.
Authors
Bernard Payrastre
1
,
Agnès Ribes
2
Affiliations
1
INSERM U1048 and Université Toulouse III Paul Sabatier; Laboratoire d'Hématologie, CHU de Toulouse, Toulouse Cedex 03. bernard.payrastre@inserm.fr.
2
INSERM U1048 and Université Toulouse III Paul Sabatier; Laboratoire d'Hématologie, CHU de Toulouse, Toulouse Cedex 03.
PMID:
33386711
PMCID:
PMC7776254
DOI:
10.3324/haematol.2020.265173
No abstract available
Publication types
Editorial
Comment
MeSH terms
Agammaglobulinaemia Tyrosine Kinase
Aspirin*
Humans
Lectins, C-Type
Platelet Activation
Protein Kinase Inhibitors*
Substances
Lectins, C-Type
Protein Kinase Inhibitors
Agammaglobulinaemia Tyrosine Kinase
Aspirin